While highest class of evidence data on effective pediatric heart failure therapies are lacking, it is commonly accepted that ACE‐inhibitors (e.g., captopril, enalapril, lisinopril) or angiotensin receptor blockers (e.g., losartan, valsartan) and beta‐blockers (e.g., carvedilol, metoprolol) form the cornerstone of effective pediatric heart failure therapy for dilated cardiomyopathies of various etiologies.21, 22, 23. This evidence concerns the gene ACE and heart failure.